381 related articles for article (PubMed ID: 20658513)
1. Prospects for immunisation against Marburg and Ebola viruses.
Geisbert TW; Bausch DG; Feldmann H
Rev Med Virol; 2010 Nov; 20(6):344-57. PubMed ID: 20658513
[TBL] [Abstract][Full Text] [Related]
2. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.
Geisbert TW; Feldmann H
J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1075-81. PubMed ID: 21987744
[TBL] [Abstract][Full Text] [Related]
3. Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
Matassov D; Mire CE; Latham T; Geisbert JB; Xu R; Ota-Setlik A; Agans KN; Kobs DJ; Wendling MQS; Burnaugh A; Rudge TL; Sabourin CL; Egan MA; Clarke DK; Geisbert TW; Eldridge JH
J Virol; 2018 Feb; 92(3):. PubMed ID: 29142131
[TBL] [Abstract][Full Text] [Related]
4. Progress in filovirus vaccine development: evaluating the potential for clinical use.
Falzarano D; Geisbert TW; Feldmann H
Expert Rev Vaccines; 2011 Jan; 10(1):63-77. PubMed ID: 21162622
[TBL] [Abstract][Full Text] [Related]
5. Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses.
Lehrer AT; Chuang E; Namekar M; Williams CA; Wong TAS; Lieberman MM; Granados A; Misamore J; Yalley-Ogunro J; Andersen H; Geisbert JB; Agans KN; Cross RW; Geisbert TW
Front Immunol; 2021; 12():703986. PubMed ID: 34484200
[TBL] [Abstract][Full Text] [Related]
6. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections.
Swenson DL; Wang D; Luo M; Warfield KL; Woraratanadharm J; Holman DH; Dong JY; Pratt WD
Clin Vaccine Immunol; 2008 Mar; 15(3):460-7. PubMed ID: 18216185
[TBL] [Abstract][Full Text] [Related]
7. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.
Geisbert TW; Geisbert JB; Leung A; Daddario-DiCaprio KM; Hensley LE; Grolla A; Feldmann H
J Virol; 2009 Jul; 83(14):7296-304. PubMed ID: 19386702
[TBL] [Abstract][Full Text] [Related]
8. Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.
Suschak JJ; Schmaljohn CS
Hum Vaccin Immunother; 2019; 15(10):2359-2377. PubMed ID: 31589088
[TBL] [Abstract][Full Text] [Related]
9. Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection.
Geisbert TW; Strong JE; Feldmann H
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S91-7. PubMed ID: 26063223
[TBL] [Abstract][Full Text] [Related]
10. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates.
Mire CE; Miller AD; Carville A; Westmoreland SV; Geisbert JB; Mansfield KG; Feldmann H; Hensley LE; Geisbert TW
PLoS Negl Trop Dis; 2012; 6(3):e1567. PubMed ID: 22448291
[TBL] [Abstract][Full Text] [Related]
11. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.
Mire CE; Geisbert JB; Marzi A; Agans KN; Feldmann H; Geisbert TW
PLoS Negl Trop Dis; 2013; 7(12):e2600. PubMed ID: 24367715
[TBL] [Abstract][Full Text] [Related]
12. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.
Geisbert TW; Daddario-Dicaprio KM; Geisbert JB; Reed DS; Feldmann F; Grolla A; Ströher U; Fritz EA; Hensley LE; Jones SM; Feldmann H
Vaccine; 2008 Dec; 26(52):6894-900. PubMed ID: 18930776
[TBL] [Abstract][Full Text] [Related]
13. A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.
Callendret B; Vellinga J; Wunderlich K; Rodriguez A; Steigerwald R; Dirmeier U; Cheminay C; Volkmann A; Brasel T; Carrion R; Giavedoni LD; Patterson JL; Mire CE; Geisbert TW; Hooper JW; Weijtens M; Hartkoorn-Pasma J; Custers J; Grazia Pau M; Schuitemaker H; Zahn R
PLoS One; 2018; 13(2):e0192312. PubMed ID: 29462200
[TBL] [Abstract][Full Text] [Related]
14. Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses.
Grant-Klein RJ; Altamura LA; Schmaljohn CS
Virus Res; 2011 Dec; 162(1-2):148-61. PubMed ID: 21925552
[TBL] [Abstract][Full Text] [Related]
15. Ebola and Marburg virus vaccines.
Reynolds P; Marzi A
Virus Genes; 2017 Aug; 53(4):501-515. PubMed ID: 28447193
[TBL] [Abstract][Full Text] [Related]
16. [Ebola and Marburg viruses: the humans strike back].
Alazard-Dany N; Ottmann Terrangle M; Volchkov V
Med Sci (Paris); 2006 Apr; 22(4):405-10. PubMed ID: 16597410
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene inserts.
Sheets RL; Stein J; Bailer RT; Koup RA; Andrews C; Nason M; He B; Koo E; Trotter H; Duffy C; Manetz TS; Gomez P
J Immunotoxicol; 2008 Jul; 5(3):315-35. PubMed ID: 18830892
[TBL] [Abstract][Full Text] [Related]
18. A single shot against Ebola and Marburg virus.
Baize S
Nat Med; 2005 Jul; 11(7):720-1. PubMed ID: 16015361
[No Abstract] [Full Text] [Related]
19. [Ebola and Marburg hemorrhagic fever viruses: update on filoviruses].
Leroy E; Baize S; Gonzalez JP
Med Trop (Mars); 2011 Apr; 71(2):111-21. PubMed ID: 21695865
[TBL] [Abstract][Full Text] [Related]
20. [Marburg and Ebola hemorrhagic fevers--pathogens, epidemiology and therapy].
Stock I
Med Monatsschr Pharm; 2014 Sep; 37(9):324-30; quiz 331-2. PubMed ID: 25282746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
